ESPE Abstracts (2014) 82 P-D-2-2-463

Recombinant Human GH Effects on Growth and Clinical Status in Cystic Fibrosis

Robabeh Ghergherehchi, Mandana Rafeey, Afshin Habibzadeh, Masoud Zamani, Khalil Ansarin & Mahnaz Sadeghi Shabestari

Tabriz University of Medical Sciences, Tabriz, Iran

Background: Growth retardation is a common finding in cystic fibrosis (CF) patients. Recombinant human GH (rhGH) has shown promising results in improving weight, height and clinical status of CF patients.

Objective and hypotheses: In this study we aim to evaluate efficacy of rhGH on growth and clinical status in CF patients.

Method: In this prospective clinical trial we recruited 34 CF patients (58.8% male with mean age of 62.05±31.11 months). Patients were followed for 6 months without treatment and then were treated with rhGH 0.35 mg/kg per week for the next 6 months. Measurements included height, weight, growth velocity, pulmonary function, hospitalizations, and outpatient antibiotic use.

Results: Growth velocity, IGF1 levels, hospitalization, and antibiotic therapy were significantly improved after rhGH treatment. 18 patients underwent pulmonary function evaluations including forced vital capacity and forced expiratory volume in 1 min which showed no significant difference with baseline findings.

Conclusion: In conclusion, these results show significant effects of rhGH treatment on growth and clinical status of CF patients.

Article tools

My recent searches

No recent searches.